Sabine Zitzmann-Kolbe obtained her PhD in the field of phage display. She spend her postdoc at the Nuclear Medicine department in Heidelberg investigating tumor targeting peptides labelled with radioisotopes for therapy and diagnosis. Later as a scientist at Bayer-Schering she worked on the development of F-18 PET tracers for differential tumor diagnosis. Since 2017 she is working as senior scientist and lab head on the preclinical development of targeted alpha tracers for the treatment of cancer at Bayer AG in Berlin.